A daily injection that builds new bone rather than slowing its loss. Spine fractures fall sharply, fractures elsewhere fall substantially, and bone density rises at every site measured — in men, in women, and in the very old. Gains hold only when a bone-preserving drug follows the course. Almost every trial was designed and funded by the maker. (Full Review)

Protocol

Standard dose

80 μg once daily

Subcutaneously into the periumbilical abdominal region, using the multi-dose pen, up to 24 months of cumulative lifetime parathyroid-hormone-analog exposure

Sequencing approach

Anabolic first

Abaloparatide for 18–24 months, then immediate transition to an antiresorptive; reverse sequencing yields smaller gains, especially at the hip

Time of day

Evening

So that transient dizziness, nausea, and heart rate elevation occur during rest rather than during activity or driving

Time to effect

Fracture protection

18 months

Accrues over the course; no perceptible day-to-day effect

Bone density

6 months

First meaningful density change appears at the 6-month scan

Bone formation markers

Within weeks

P1NP rises steeply in the first month; trabecular bone score gains significant at 12 weeks

Benefits

High: Vertebral fracture risk reduction; nonvertebral fracture risk reduction; bone mineral density gain at spine, hip, and femoral neck

Medium: Bone quality and structural strength beyond density; lower hypercalcemia burden than teriparatide

Low: Rapid onset of anabolic response

Speculative: Cardiovascular event reduction; enhanced spinal fusion and implant fixation

Contraindications

Increased baseline osteosarcoma risk (Paget's disease of bone, unexplained alkaline phosphatase elevation, open growth plates, prior skeletal radiation, bone metastases, hereditary predisposition such as Li-Fraumeni syndrome)

Pre-existing hypercalcemia, primary hyperparathyroidism, or active urolithiasis (within the past 12 months)

Severe kidney impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m²)

Already accumulated 24 months of lifetime parathyroid-hormone-analog exposure (counting teriparatide)

Pregnancy, breastfeeding, and premenopausal women of childbearing potential

Known hypersensitivity to abaloparatide or its inactive ingredients

Key Interactions

Digoxin

Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide)

Antihypertensives and nitrates (doxazosin, terazosin, isosorbide, nitroglycerin)

Lithium

Calcium-containing antacids

High-dose vitamin D (above replacement level)

Calcium supplements (roughly 1,000 mg daily from diet plus supplement)

Vitamin K2 and magnesium

Prior or concurrent antiresorptives (alendronate, zoledronate, denosumab)

Romosozumab and teriparatide (avoid concurrent use)

Risk & Side Effects

High: Administration site reactions; orthostatic hypotension and dizziness; nausea; palpitations and transient heart rate increase

Medium: Hypercalcemia and hypercalciuria; rapid bone loss after stopping without follow-on therapy; headache

Low: Hyperuricemia; anti-drug antibody formation

Speculative: Osteosarcoma

Monitoring

Marker	Target	Why
Serum calcium (albumin-corrected)	8.8–10.0 mg/dL	Detects the drug's principal biochemical toxicity
25-hydroxyvitamin D	40–60 ng/mL	Determines whether new bone can mineralise
Parathyroid hormone (PTH)	15–35 pg/mL	Excludes hyperparathyroidism, which contraindicates treatment
Alkaline phosphatase	50–90 U/L	Unexplained elevation flags Paget's disease or skeletal malignancy
P1NP (procollagen type I N-terminal propeptide)	Rise of ≥40% from the individual's own baseline by 3 months	Confirms the bone-building signal has engaged
CTX	Below the pretreatment baseline or modestly above	Shows whether resorption is tracking formation
24-hour urine calcium	100–250 mg/24 h	Detects hypercalciuria before stones form
Estimated glomerular filtration rate (eGFR)	≥60 mL/min/1.73 m²	Governs calcium and peptide clearance
Serum uric acid	3.5–6.0 mg/dL	Rises predictably on treatment; matters in gout
Lumbar spine and total hip DXA T-score	Improvement toward better than −2.5	The endpoint the whole course is aimed at
Trabecular bone score (TBS)	Above 1.31, or rising from own baseline	Captures bone structure that density alone misses

Cadence: Serum calcium at 4 weeks and after any dose or co-medication change; bone turnover markers at 3 months; calcium and kidney function every 6 months thereafter; repeat DXA at 12 and 24 months

Qualitative Assessment

Height measured annually against a fixed wall-mounted scale — a loss of 2 cm or more suggests a new vertebral fracture even without pain
New or changed back pain, particularly sudden pain that worsens on standing and eases lying down
Lightheadedness or unsteadiness in the hours after dosing, and whether it is fading over the first weeks
Nausea severity and whether it is interfering with eating or with adherence to the daily injection
Injection site tolerance — persistent reactions signal a need to change rotation technique before adherence fails
Confidence in movement and balance, and any near-falls, which predict fracture more directly than density does

Abaloparatide for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment